Tag: AMD drug

Cell and Gene Therapy, Industry

Regeneron, in search of an eye gene therapy, turns to a young biotech

April 6, 2022

Via: Biopharma Dive

Excluding its coronavirus antibody drug, Regeneron has long counted Eylea as its top-selling product. Last year, net sales of the eye therapy totaled $5.8 billion in the U.S. and $3.6 billion across the rest of the world, where Regeneron’s partner […]